GL7970 - L-alpha-Phosphatidylcholine, 90% (8002-43-5)
Sometimes there is confusion between the terms lecithin and phosphatidyl choline. Lecithin products usually contain a mixture of phospholipids. For decades, most lecithin supplements only contained from 10 to 20% phosphotidyl choline. However, as the benefits of phosphatidyl choline (PC) became better recognized, lecithin products with higher percentages of PC became more readily available. Products containing a high concentration of phosphatidyl choline are actually purified extracts of lecithin, which are generally labeled as phosphatidyl choline rather than lecithin.
Phosphatidyl choline (PC) is the most abundant member of a class of compounds called the phospholipids. These compounds are structurally composed of a glycerol backbone, fatty acids, a phosphate group, and a hydrophilic organic derivative, which is choline in the phosphatidyl choline molecule. Phospholipids form lipid bilayers, which are a major part of the architectural structure of cellular membranes. The types of fats and the degree of their saturation help to determine cell membrane characteristics such as fluidity and barrier functions. PC and other phospholipids also enable the cellular signaling system that is responsible for intercellular communication. [ ]
Here is what people are saying about Phosphatidyl Choline
|Amount Per Serving||% Daily Value|
||Calories from Fat
|*Daily Value not established
Related to Phosphatidyl choline:
Numerous neuropsychiatric diseases, such as tardive dyskinesia, Huntington’s chorea, ataxias, Tourette’s syndrome, schizophrenia, and Alzheimer’s disease are associated with under activity of cholinergic neurons. Although cholinergic precursors could theoretically be clinically beneficial for these conditions, most scientific studies with choline or phosphatidyl choline have reported either minimal or no benefit for these clinical conditions.
1. The author delineates the emergence of an important concept in the Neurochemistry of mental illness, that of a Cholinergic Factor in Mania. This concept which evolved steadily over a period of 22 years from 1950-1972, the author believes has given us our first significant insight into the etiology and treatment of the Manic state. 2. In addition, the author examines the Adrenergic-Cholinergic hypothesis of Mania and Depression and the Brain Cholinergic- Adrenergic Balance hypothesis for Mania and Schizophrenia. 3. Also described in this article are some successful preliminary attempts by others, to treat Mania with Phosphatidyl Choline and the author will present, for the first time, data relating to success with the use of Phosphatidyl Choline in bringing about permanent remission of mania in 10 treatment subjects since 1983. 4. In conclusion the author proposes a Cholinergic Insufficiency Hypothesis as a primary factor in the causation of Mania and comments on a presumptive role in the modulation and balance of Adrenergic Dominance by Presynaptic Receptors positioned on the Nerve Terminals of Adrenergic Neurons.